DELTA-Q-TECHNOLOGIES
22.4.2020 21:26:09 CEST | Business Wire | Press release
Delta-Q Technologies (Delta-Q), a leader in battery charging solutions for electric drive vehicles and machines, announced the planned release of a four-part educational series called “The Charge,” which includes three on-demand videos followed by a one-hour live webinar.
Parties interested in viewing the educational content can register for access by clicking on the following link: www.delta-q.com/thechargeseries .
Hosted by Delta-Q, “The Charge,” will share best practices around onboard battery charging, as well as how to leverage software and charger data to maximize machine runtimes. Topics will include how original equipment manufacturers (OEMs) can design and validate chargers onboard electric machines, mitigate battery failure and safety risks with charger software profiles, and extract charger data to help reduce maintenance spending and improve overall usage. The live webinar on Day 4, will provide a Q&A with Delta-Q’s charging experts and an announcement on a new solution that will redefine charger expectations for the floor care industry.
Nicholas Dohmeier, Senior Power Electronics Engineer with Delta-Q, will lead the four-part series. Each video consists of 3-4 minutes of subject matter, the fourth and final webinar will conclude with a live Q&A and product announcement. The full series schedule is as follows:
“The Charge” Educational Series Schedule:
- Day 1: May 18, 2020: Get Rid of Charging Failures with Onboard Battery Charger Reliability and Validation Testing
- Day 2: May 19, 2020: Mitigate Premature Battery Failure with Charger Software
- Day 3: May 20, 2020: How Leveraging Your Floor Machine’s Charger Data Can Save You Thousands of Dollars
- Day 4: May 21, 2020: Q&A and New Product Announcement
“We are excited to share our new on-demand series to help OEMs make informed decisions and set their organizations up for long-term success,” says Dohmeier. “Our four-part educational series will prepare manufacturers who are interested in designing electric equipment with modern charging solutions.”
About Delta-Q Technologies:
Delta-Q Technologies, a leading provider of battery charging solutions that improve the performance and reliability of electric drive vehicles and industrial equipment, has more than 20 years of experience helping tier 1 OEMs electrify their products, while its engineering team has a combined experience of more than 60 years working with CAN programming and telematic systems. The company has become the supplier of choice to many of the world’s leading manufacturers of electric golf cars, lift trucks, aerial work platforms, motorcycles and scooters, floor care machines, and utility and recreational vehicles. Delta-Q is headquartered in Vancouver, Canada with a local presence in the U.S., Europe, and Asia. For more information, please visit www.delta-q.com or follow company updates on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005918/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom